Clicky

CrystalGenomics Inc(083790)

Description: CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.


Keywords: Cancer Biopharmaceutical Infectious Diseases Antibiotics Drug Discovery Microbiology Cloning Staphylococcus Aureus Bacterial Disease Vancomycin Glycopeptide Antibiotics

Home Page: www.cgxinc.com

Tower A, Korea Bio Park
Seongnam-si, 463-400
South Korea
Phone: 82 3 1628 2700


Officers

Name Title
Willim Schmdit Exec. Officer
Hui-Sung Lee Exec. Officer
Jong-Ryu Choi Exec. Officer
Doh-Young Lee Exec. Officer
Dr. Joong-Myung Cho Ph.D. Chairman, Founder, CEO & Pres
Dr. Seonggu Ro Ph.D. Co-Founder, Chief Technology Officer, Exec. VP and Director
Dr. In Chul Chung VP & CFO
Mr. Sang-Cheon Ahn Exec. Managing Director and Director
Dr. Yong-Rae Hong Exec. MD & Research Head of Institute for Drug Discovery
Cheol-Soon Lee Exec. Officer

Exchange: KQ

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 9.3518
IPO Date: 2006-01-06
Fiscal Year End: December
Full Time Employees: 55
Back to stocks